Calvarial Tuberculosis With Intracranial Tuberculomas: A Rare Association

Jain, Rajendra Singh; Prakash, Swayam; Mathur, Tarun; Handa, Rahul; Nagpal, Kadam
August 2013
Journal of Neurology Research;2013, Vol. 3 Issue 3, p130
Academic Journal
Case Study
Tuberculosis is an infectious disease caused by the acid-fast bacilli Mycobacterium tuberculosis that usually affect the lungs although it may affect any organ. Though incidence of tuberculosis is on rise especially in third world countries like India, tuberculous osteitis of the cranial bones, also known as calvarial tuberculosis, is an uncommon manifestation of disseminated tuberculosis. Calvarial tuberculosis as primary tubercular infection is very rare and rarer still is its association with tuberculomas. We report a case with multiple osteolytic cranial lesions and tuberculomas without focus of infection elsewhere in the body.


Related Articles

  • tuberculostatic.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2385 

    A definition of the medical term "tuberculostatic," which refers to inhibiting the growth of tubercle bacillus, is presented.

  • An Approach for the Rational Design of New Antituberculosis Agents. Pasqualoto, K.F.M.; Ferreira, E.I. // Current Drug Targets;Dec2001, Vol. 2 Issue 4, p427 

    Tuberculosis (TB) kills more youth and adults than any other infectious disease in the world today. The emergence of new strains of Mycobacterium tuberculosis resistant to some or all current antituberculosis drugs is a serious and crescent problem. The resistance is often a corollary to HIV...

  • Gatifloxacin in combination with rifampicin in a murine tuberculosis model. Michael Cynamon; Mary R. Sklaney; Carolyn Shoen // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p429 

    Objectives Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis. Several regimens of gatifloxacin in combination with rifampicin were compared with isoniazid plus rifampicin in a mouse tuberculosis model. Methods C57BL/6 mice were infected...

  • A silver Nanoparticle/Poly (8-Anilino-1-Naphthalene Sulphonic Acid) Bioelectrochemical Biosensor System for the Analytical Determination of Ethambutol. Ngece, Rachel F.; West, Natasha; Ndangili, Peter M.; Olowu, Rasaq A.; Williams, Avril; Hendricks, Nicolette; Mailu, Stephen; Baker, Priscilla; Iwuoha, Emmanuel // International Journal of Electrochemical Science;Jun2011, Vol. 6, p1820 

    Ethambutol (2S, 2'S)-2, 2'-(ethane-1, 2-diyldiimino) dibutan-1-ol) is a first-line antitubercular drug effective against actively growing Mycobacterium tuberculosis. Resistance of the mycobacterium to ethambutol among tuberculosis (TB) patients results from inadequate or inappropriate dosing of...

  • CHIH-DFT determination of the molecular structure infrared spectra, UV spectra and chemical reactivity of three antitubercular compounds: Rifampicin, Isoniazid and Pyrazinamide. Alejandra Favila; Marco Gallo; Daniel Glossman-Mitnik // Journal of Molecular Modeling;Apr2007, Vol. 13 Issue 4, p505 

    Abstract??Three of the most frequent antitubercular agents employed against Mycobacterium tuberculosis are: Rifampicin, Isoniazid and Pyrazinamide. It has been proven that the use of these antitubercular agents together, shortens the treatment period from 12?18?months to 6?months...

  • Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR. Nakajima, Chie; Rahim, Zeaur; Fukushima, Yukari; Sugawara, Isamu; van der Zanden, Adri G. M.; Tamaru, Aki; Suzuki, Yasuhiko // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p118 

    Background: Species identification of isolates belonging to the Mycobacterium tuberculosis complex (MTC) seems to be important for the appropriate treatment of patients, since M. bovis is naturally resistant to a first line anti-tuberculosis (TB) drug, pyrazinamide, while most of the other MTC...

  • Antitubercular Properties of Substituted Hydroxycyclohexadienones. Shah, Manish; Wells, Geoffrey; Bradshaw, Tracey D.; Laughton, Charles A.; Stevens, Malcolm F.G.; Westwell, Andrew D. // Letters in Drug Design & Discovery;Aug2006, Vol. 3 Issue 6, p419 

    The in vitro evaluation of a series of (hetero)aromatic-substituted 4-hydroxycyclohexa-2,5-dienones (quinols) and analogues against M. tuberculosis is reported. The most active compound in the series was found to be 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone 1a with a minimum...

  • In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India. Singh, Mradula; Chauhan, D. S.; Gupta, Pushpa; Das, R.; Srivastava, R. K.; Upadhyay, Prashant; Singh, Pushpendra; Srivastava, K.; Faujdar, Jaya; Jaudaun, G. P. S.; Yadav, V. S.; Sharma, V. D.; Venkatesan, K.; Sachan, S.; Sachan, P.; Katoch, K.; Katoch, V. M. // Indian Journal of Medical Research;May2009, Vol. 129 Issue 5, p542 

    Background & objectives: Fluoroquinolones (FQs) are important drugs used for treatment of drug resistant tuberculosis and are also now being considered as first line drugs to shorten the duration of treatment of tuberculosis (TB). In order to find out useful FQs for treatment of tuberculosis,...

  • Shikimate Kinase: A Potential Target for Development of Novel Antitubercular Agents. Pereira, José H.; Vasconcelos, Igor B.; Oliveira, Jaim S.; Caceres, Rafael A.; de Azevedo Jr., Walter F.; Basso, Luis A.; Santos, Diogenes S. // Current Drug Targets;Mar2007, Vol. 8 Issue 3, p459 

    Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis. However, no new classes of drugs for TB have been developed in the past 30 years. Therefore there is an urgent need to develop faster acting and effective new antitubercular agents,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics